FDA to warn of Guillain-Barré risk for Johnson & Johnson vaccine: report

Business

Business Insider 12 July, 2021 - 02:31pm 11 views

“No Rules Rules: Netflix and the Culture of Reinvention”

Get it now on Libro.fm using the button below.

About 100 cases of Guillain-Barré syndrome (GBS) have been reported among people who received J&J's vaccine, the US Centers for Disease Control and Prevention said in a statement sent to Insider.

"Reports of GBS after receipt of the J&J/Janssen COVID-19 Vaccine in the Vaccine Adverse Event Reporting System (VAERS) are rare, but do likely indicate a small possible risk of this side effect following this vaccine," the CDC said. "These cases have largely been reported about two weeks after vaccination and mostly in males, many aged 50 years and older."

Health authorities continue to stress that J&J's vaccine is safe, and that its benefits outweigh the risks, as unvaccinated people are at the greatest risk of hospitalization and death from the coronavirus.

The US Food and Drug Administration did not immediately respond to requests for comment. J&J did not immediately respond to Insider's inquiry either.

Vaccines from Moderna and from Pfizer-BioNTech are being used much more frequently in the US, and those shots haven't been linked to the condition. About 12.8 million doses of J&J's shot have been administered across the US.

About 3,000 to 6,000 people develop Guillain-Barré each year, according to the CDC. The disorder often follows infections with a virus or bacteria. The syndrome causes muscle weakness and sometimes paralysis, which is usually temporary, and it is more common among older men.

The warning would be a second black mark for J&J's shot. The vaccine has also been connected to cases of rare but serious blood clots.

US health officials halted use of J&J vaccine on April 13 after more than a dozen people — mostly women under the age of 50 — developed a rare type of blood clot after getting the shot. 

Three of the cases were fatal, according to data shared by the CDC at the time.

Regulators allowed vaccine distribution to resume on April 23, with a new warning attached.

The cause of Guillain-Barré isn't fully understood. A 1976 version of the flu vaccine, developed to fight a potential pandemic strain of influenza, was linked to a slightly higher risk of developing GBS.

Read full article at Business Insider

The FDA issued a warning about a rare paralyzing syndrome linked to Johnson & Johnson's coronavirus vaccine

Business Insider 12 July, 2021 - 12:00am

“No Rules Rules: Netflix and the Culture of Reinvention”

Get it now on Libro.fm using the button below.

100 cases of Guillain-Barré syndrome have been reported among people who received J&J's vaccine, the FDA said in a statement, and the FDA changed its fact sheets on the vaccine for providers and patients.

"Reports of GBS after receipt of the J&J/Janssen COVID-19 Vaccine in the Vaccine Adverse Event Reporting System (VAERS) are rare, but do likely indicate a small possible risk of this side effect following this vaccine," the Centers for Disease Control and Prevention said in a separate statement. "These cases have largely been reported about two weeks after vaccination and mostly in males, many aged 50 years and older."

The FDA said 95 of the 100 cases were hospitalized, and one person died. Supportive care is generally recommended for any case of GBS, as patients are at risk of developing neuromuscular respiratory failure, and requiring a ventilator.

The Washington Post first reported that the FDA planned to issue a warning earlier on Monday.

Health authorities continue to stress that J&J's vaccine is safe, and that its benefits outweigh the risks. Unvaccinated people are still at the greatest risk of hospitalization and death from the coronavirus. 

Still, the warning is another black mark for J&J's shot. The vaccine has also been connected to cases of rare but serious blood clots.

J&J said it's been in discussions with the FDA and other regulators about the cases of Guillain-Barré. The company noted that while the syndrome is very rare, the rate of reported cases after vaccination exceeds what you'd expect "by a small degree."

Vaccines from Moderna and from Pfizer-BioNTech are being used much more frequently in the US, and those shots haven't been linked to the condition. About 12.8 million doses of J&J's shot have been administered across the US.

About 3,000 to 6,000 people develop Guillain-Barré each year, the CDC said. The disorder often follows infections with a virus or bacteria. The syndrome causes muscle weakness and sometimes paralysis, which is usually temporary, and it is more common among older men.

Some of the first symptoms of the syndrome can include a tingling in the feet or hands. Others include difficulty swallowing, speaking, chewing, seeing, or facial paralysis.

The muscle weakness prompted by GBS can often make it difficult to walk or climb stairs, a tell-tale sign many people use to know to seek care, according to the National Institutes of Health.

In April, US health officials halted use of the J&J vaccine after more than a dozen people — mostly women under the age of 50 — developed a rare type of blood clot after getting the shot.

Three of the cases were fatal, showed data shared by the CDC at the time.

Regulators allowed vaccine distribution to resume on April 23, with a new warning attached.

The cause of Guillain-Barré isn't fully understood. A 1976 version of the flu vaccine, developed to fight a potential pandemic strain of influenza, was linked to a slightly higher risk of developing GBS.

Guillain-Barré

Business Stories

Top Stores